(en) L. Kuhlwilm, C. Schönfeldt‐Lecuona, M. Gahr et B. J. Connemann, « The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome », Acta Psychiatrica Scandinavica, vol. 142, no 3, , p. 233–241 (ISSN0001-690X et 1600-0447, DOI10.1111/acps.13215, lire en ligne, consulté le )
Kazuo Mihara, Tsuyoshi Kondo, Akihito Suzuki et Norio Yasui-Furukori, « Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome », American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, vol. 117B, no 1, , p. 57–60 (ISSN1552-4841, PMID12555236, DOI10.1002/ajmg.b.10025, lire en ligne, consulté le )
G. Northoff, « Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology », Journal of Neural Transmission (Vienna, Austria: 1996), vol. 109, no 12, , p. 1453–1467 (ISSN0300-9564, PMID12486486, DOI10.1007/s00702-002-0762-z, lire en ligne, consulté le )
(en) Kim S. J. Lao, Jiaxi Zhao, Joseph Edgar Blais et Lam Lam, « Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study », CNS Drugs, vol. 34, no 11, , p. 1165–1175 (ISSN1179-1934, DOI10.1007/s40263-020-00767-9, lire en ligne, consulté le )
(en) Michael Schneider, Johannes Regente, Timo Greiner et Stephanie Lensky, « Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015 », European Archives of Psychiatry and Clinical Neuroscience, vol. 270, no 1, , p. 23–33 (ISSN1433-8491, DOI10.1007/s00406-018-0959-2, lire en ligne, consulté le )
doi.org
(en) Kim S. J. Lao, Jiaxi Zhao, Joseph Edgar Blais et Lam Lam, « Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study », CNS Drugs, vol. 34, no 11, , p. 1165–1175 (ISSN1179-1934, DOI10.1007/s40263-020-00767-9, lire en ligne, consulté le )
(en) Michael Schneider, Johannes Regente, Timo Greiner et Stephanie Lensky, « Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015 », European Archives of Psychiatry and Clinical Neuroscience, vol. 270, no 1, , p. 23–33 (ISSN1433-8491, DOI10.1007/s00406-018-0959-2, lire en ligne, consulté le )
(en) L. Kuhlwilm, C. Schönfeldt‐Lecuona, M. Gahr et B. J. Connemann, « The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome », Acta Psychiatrica Scandinavica, vol. 142, no 3, , p. 233–241 (ISSN0001-690X et 1600-0447, DOI10.1111/acps.13215, lire en ligne, consulté le )
Kazuo Mihara, Tsuyoshi Kondo, Akihito Suzuki et Norio Yasui-Furukori, « Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome », American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, vol. 117B, no 1, , p. 57–60 (ISSN1552-4841, PMID12555236, DOI10.1002/ajmg.b.10025, lire en ligne, consulté le )
G. Northoff, « Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology », Journal of Neural Transmission (Vienna, Austria: 1996), vol. 109, no 12, , p. 1453–1467 (ISSN0300-9564, PMID12486486, DOI10.1007/s00702-002-0762-z, lire en ligne, consulté le )
(en) Kim S. J. Lao, Jiaxi Zhao, Joseph Edgar Blais et Lam Lam, « Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study », CNS Drugs, vol. 34, no 11, , p. 1165–1175 (ISSN1179-1934, DOI10.1007/s40263-020-00767-9, lire en ligne, consulté le )
(en) Michael Schneider, Johannes Regente, Timo Greiner et Stephanie Lensky, « Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015 », European Archives of Psychiatry and Clinical Neuroscience, vol. 270, no 1, , p. 23–33 (ISSN1433-8491, DOI10.1007/s00406-018-0959-2, lire en ligne, consulté le )
S. Dhib-Jalbut, R. Hesselbrock, M. M. Mouradian et E. D. Means, « Bromocriptine treatment of neuroleptic malignant syndrome », The Journal of Clinical Psychiatry, vol. 48, no 2, , p. 69–73 (ISSN0160-6689, PMID3804991, lire en ligne, consulté le )
Kazuo Mihara, Tsuyoshi Kondo, Akihito Suzuki et Norio Yasui-Furukori, « Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome », American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, vol. 117B, no 1, , p. 57–60 (ISSN1552-4841, PMID12555236, DOI10.1002/ajmg.b.10025, lire en ligne, consulté le )
G. Northoff, « Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology », Journal of Neural Transmission (Vienna, Austria: 1996), vol. 109, no 12, , p. 1453–1467 (ISSN0300-9564, PMID12486486, DOI10.1007/s00702-002-0762-z, lire en ligne, consulté le )
S. Dhib-Jalbut, R. Hesselbrock, M. M. Mouradian et E. D. Means, « Bromocriptine treatment of neuroleptic malignant syndrome », The Journal of Clinical Psychiatry, vol. 48, no 2, , p. 69–73 (ISSN0160-6689, PMID3804991, lire en ligne, consulté le )
wiley.com
onlinelibrary.wiley.com
(en) L. Kuhlwilm, C. Schönfeldt‐Lecuona, M. Gahr et B. J. Connemann, « The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome », Acta Psychiatrica Scandinavica, vol. 142, no 3, , p. 233–241 (ISSN0001-690X et 1600-0447, DOI10.1111/acps.13215, lire en ligne, consulté le )